-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In most cases, sudden cardiac death (SCD) is associated with severe coronary heart disease.
whether C-IMT is an alternative indicator of subclinical atherosclerosis in the general population and whether it is related to SCD risk is not clear.
recently published a study in JAHA, an authoritative journal in the field of cardiovascular disease, that looked at the relationship between C-IMT and SCD risk.
researchers assessed 20,862 participants: 15,307 participants in the Community Atherosclerosis Risk (ARIC) study and 5,555 participants in the Cardiovascular Health Study (CHS).
the thickness of the inner membrane of C-IMT and the total artery of the neck by ultrasound at baseline.
the plaques are judged by trained researchers.
an average of 23.5 years of follow-up, 569 participants in the ARIC study had SCDs (1.81 cases per 1,000 people per year).
the correction of traditional risk factors and time-change regulatory factors, the average C-IMT and cervical arterial endometrial mid-layer thickness were associated with SCD risk: the risk ratio (HRs) and 95% CI were 1.64 (1.15-2.63) and 1.49 (1.05-2.11), respectively, compared to the 14th quarterile.
in CHS, 302 participants had SCDs in 13.1 years (4.64 cases per 1,000 people per year).
, the maximum C-IMT is associated with SCD risk: the HR (95%CI) of the 4th quarterile is 1.75 (1.22-2.51) compared to the 14th.
plaque was associated with a 35% increase in SCD risk: HR (95%CI) in the ARIC study was 1.37 (1.13-1.67) and CHS was 1.32 (1.04-1.68).
, C-IMT is associated with SCD risk in two community-based queues.
C-IMT can be used as a marker of SCD risk and has the potential to initiate early treatment interventions to reduce risk.
.